Escitalopram

Generic Name
Escitalopram
Brand Names
Cipralex, Lexapro
Drug Type
Small Molecule
Chemical Formula
C20H21FN2O
CAS Number
128196-01-0
Unique Ingredient Identifier
4O4S742ANY
Background

Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer. Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.

Indication

Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.

Associated Conditions
Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
Associated Therapies
-

Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study

Phase 4
Conditions
Interventions
First Posted Date
2008-07-02
Last Posted Date
2009-01-27
Lead Sponsor
BeerYaakov Mental Health Center
Target Recruit Count
20
Registration Number
NCT00708396
Locations
🇮🇱

Beer-Yaacov MHC, Beer-Yaacov, Israel

Treatment Youth With Obsessive-Compulsive Disorder

First Posted Date
2008-07-02
Last Posted Date
2008-07-02
Lead Sponsor
University of Ottawa
Target Recruit Count
40
Registration Number
NCT00708240
Locations
🇨🇦

University of Ottawa Institute of Mental Health Research, Ottawa, Ontario, Canada

Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram

Phase 4
Completed
Conditions
Interventions
First Posted Date
2008-07-01
Last Posted Date
2016-10-17
Lead Sponsor
Indiana University School of Medicine
Target Recruit Count
17
Registration Number
NCT00707863
Locations
🇺🇸

Indiana University Adult Psychiatric Clinic, Indianapolis, Indiana, United States

A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2008-06-23
Last Posted Date
2019-09-17
Lead Sponsor
Kunming Medical University
Target Recruit Count
200
Registration Number
NCT00703742
Locations
🇨🇳

The First Affiliated Hospital of Kunming Medical College, Kunming, Yunnan, China

Progression Delaying Effect of Escitalopram in Alzheimer's Disease

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2008-06-20
Last Posted Date
2014-06-13
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
74
Registration Number
NCT00702780
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

🇰🇷

Konkuk University Hospital, Seoul, Korea, Republic of

🇰🇷

Kangwon National University Hospital, Chuncheon, Korea, Republic of

and more 1 locations

International Study to Predict Optimised Treatment - in Depression

First Posted Date
2008-06-09
Last Posted Date
2018-07-11
Lead Sponsor
BRC Operations Pty. Ltd.
Target Recruit Count
2688
Registration Number
NCT00693849
Locations
🇺🇸

Shanti Clinical Trials, Colton, California, United States

🇺🇸

A.D.D. Treatment Center, Mission Viejo, California, United States

🇺🇸

Veteran Affairs/Stanford University, Stanford, California, United States

and more 16 locations

Escitalopram in Adult Patients With Major Depressive Disorder

Phase 3
Completed
Conditions
Interventions
First Posted Date
2008-04-29
Last Posted Date
2010-05-11
Lead Sponsor
Forest Laboratories
Target Recruit Count
877
Registration Number
NCT00668525
Locations
🇺🇸

Forest Investigative Site, Seattle, Washington, United States

Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2008-04-17
Last Posted Date
2014-12-09
Lead Sponsor
Hillerod Hospital, Denmark
Target Recruit Count
47
Registration Number
NCT00660062
Locations
🇩🇰

Mental Health Centre Copenhagen Department O, Copenhagenl, Denmark

Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation

Early Phase 1
Conditions
First Posted Date
2008-04-11
Last Posted Date
2008-04-11
Lead Sponsor
Cairo University
Target Recruit Count
100
Registration Number
NCT00656552
Locations
🇪🇬

Kasr el ainy school of medicine , Cairo university, Cairo, Egypt

Efficacy Study of Escitalopram for Depression in Patients With Diabetes

First Posted Date
2008-04-02
Last Posted Date
2008-04-02
Lead Sponsor
Sheba Medical Center
Target Recruit Count
30
Registration Number
NCT00650897
Locations
🇮🇱

Sheba Medical Center, Tel Hashomer, Israel

© Copyright 2024. All Rights Reserved by MedPath